|
|
Volumn 6, Issue 5, 2007, Pages 334-335
|
|
Where now for new drugs for atherosclerosis?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER;
ANTILIPEMIC AGENT;
APOLIPOPROTEIN A1;
ATORVASTATIN;
CHEMOKINE RECEPTOR ANTAGONIST;
CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR;
CSL 111;
DARAPLADIB;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LEUKOTRIENE RECEPTOR BLOCKING AGENT;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
LY 333013;
LY 518674;
MK 0524 A;
MK 0859;
MLN 1202;
NICOTINIC ACID;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST;
PHOSPHOLIPASE A2 INHIBITOR;
PROBUCOL SUCCINATE;
PROSTAGLANDIN RECEPTOR STIMULATING AGENT;
RIFALAZIL;
RIMONABANT;
SB 681323;
TERUTROBAN;
THROMBOXANE A2 RECEPTOR BLOCKING AGENT;
TORCETRAPIB;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VIA 2291;
ARTICLE;
ATHEROSCLEROSIS;
ATHEROSCLEROTIC PLAQUE;
BURNING SENSATION;
CARDIOVASCULAR RISK;
CAUSE OF DEATH;
CHOLESTEROL TRANSPORT;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
DEATH;
DRUG FATALITY;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG MECHANISM;
DRUG RESEARCH;
FLUSHING;
HEART INFARCTION;
HUMAN;
INHIBITION KINETICS;
MONOTHERAPY;
PRIORITY JOURNAL;
RISK REDUCTION;
SIDE EFFECT;
SKIN TINGLING;
STROKE;
SUSTAINED RELEASE FORMULATION;
TREATMENT FAILURE;
TREATMENT OUTCOME;
ANTICHOLESTEREMIC AGENTS;
ATHEROSCLEROSIS;
CHOLESTEROL ESTER TRANSFER PROTEINS;
CHOLESTEROL, HDL;
CLINICAL TRIALS, PHASE III;
HUMANS;
QUINOLINES;
|
|
EID: 34247855087
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2326 Document Type: Article |
|
Times cited : (10)
|
|
References (0)
|
